Home » Stocks » TTOO

T2 Biosystems, Inc. (TTOO)

Stock Price: $1.19 USD 0.04 (3.48%)
Updated December 3, 4:00 PM EST - Market closed
Pre-market: $1.17 -0.02 (-1.68%) Dec 4, 5:48 AM

TTOO Stock Price Chart

Key Info

Market Cap 176.07M
Revenue (ttm) 13.41M
Net Income (ttm) -50.93M
Shares Out 147.79M
EPS (ttm) -0.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $1.19
Previous Close $1.15
Change ($) 0.04
Change (%) 3.48%
Day's Open 1.16
Day's Range 1.14 - 1.21
Day's Volume 3,070,515
52-Week Range 0.28 - 2.10

TTOO Stock News

Insider Monkey - 5 days ago

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and anal...

Seeking Alpha - 2 weeks ago

A struggling diagnostics platform is benefiting from Sars-COVID-2 tailwinds. Its sars-COVID-2 test is accelerating the uptake of its diagnostic platform.

GlobeNewsWire - 3 weeks ago

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to pa...

Seeking Alpha - 4 weeks ago

T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 weeks ago

T2 Biosystems (TTOO) delivered earnings and revenue surprises of 20.00% and 32.45%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 4 weeks ago

Shares of T2 Biosystems (NASDAQ:TTOO) fell 10% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 74.19% over the past year to ($0.08...

GlobeNewsWire - 4 weeks ago

Total revenues increase by 213% on record high quarterly product sales Total revenues increase by 213% on record high quarterly product sales

Zacks Investment Research - 1 month ago

T2 Biosystems (TTOO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 month ago

John Sperzel will serve on the Industry Council of the Advisory Board John Sperzel will serve on the Industry Council of the Advisory Board

GlobeNewsWire - 1 month ago

LEXINGTON, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financia...

Zacks Investment Research - 1 month ago

Is (TTOO) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 2 months ago

Advances Development of Diagnostics for Sepsis-Causing Pathogens, Antibiotic Resistance, and Biothreat Pathogens Advances Development of Diagnostics for Sepsis-Causing Pathogens, Antibiotic Re...

Zacks Investment Research - 2 months ago

Is (TTOO) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 2 months ago

Summit will raise awareness and highlight the critical role of rapid diagnostics for bloodstream infections, sepsis and the COVID-19 virus Summit will raise awareness and highlight the critica...

GlobeNewsWire - 3 months ago

Payment Covers 65 Percent of the Average Cost of the Test Panel for Eligible Patients Payment Covers 65 Percent of the Average Cost of the Test Panel for Eligible Patients

GlobeNewsWire - 3 months ago

The T2SARS-CoV-2™ Panel runs on the FDA-cleared T2Dx® Instrument The T2SARS-CoV-2™ Panel runs on the FDA-cleared T2Dx® Instrument

Zacks Investment Research - 3 months ago

Convalescent plasma stocks moved northward following FDA's emergency plasma authorization for COVID-19 treatment. Here're three of them that should be on your watch list -

Other stocks mentioned: CERS, KMDA
Benzinga - 3 months ago

Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use ...

Other stocks mentioned: ADMA, CERS, GRFS, KMDA, LMNL, SONN, THMO
Zacks Investment Research - 3 months ago

Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.

Seeking Alpha - 3 months ago

T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q2 2020 Results - Earnings Call Transcript

Benzinga - 3 months ago

Shares of T2 Biosystems (NASDAQ: TTOO) decreased 7.49% in after-market trading after the company reported Q2 results.

GlobeNewsWire - 3 months ago

LEXINGTON, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the ...

Benzinga - 3 months ago

T2 Biosystems (NASDAQ: TTOO) announces its next round of earnings this Tuesday, August 11.

GlobeNewsWire - 3 months ago

LEXINGTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that its Board of Director...

Zacks Investment Research - 4 months ago

In the latest trading session, T2 Biosystems (TTOO) closed at $1.66, marking a +1.84% move from the previous day.

GlobeNewsWire - 4 months ago

LEXINGTON, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to ...

GlobeNewsWire - 4 months ago

LEXINGTON, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financ...

Zacks Investment Research - 4 months ago

T2 Biosystems' (TTOO) second-quarter results are likely to reflect growth in product revenues.

Zacks Investment Research - 4 months ago

In the latest trading session, T2 Biosystems (TTOO) closed at $1.62, marking a +0.62% move from the previous day.

Zacks Investment Research - 4 months ago

In the latest trading session, T2 Biosystems (TTOO) closed at $1.33, marking a -0.75% move from the previous day.

24/7 Wall Street - 5 months ago

T2 Biosystems Inc. (NASDAQ: TTOO) solidified its position as a coronavirus stock on Wednesday morning when it announced the launch of its COVID-19 molecular diagnostic test.

GlobeNewsWire - 5 months ago

The T2SARS-CoV-2™ Panel will run on the FDA cleared T2Dx® Instrument The T2SARS-CoV-2™ Panel will run on the FDA cleared T2Dx® Instrument

GlobeNewsWire - 5 months ago

Launches the T2SARS-CoV-2™ Panel under FDA EUA Guidelines Launches the T2SARS-CoV-2™ Panel under FDA EUA Guidelines

GlobeNewsWire - 5 months ago

LEXINGTON, Mass., June 26, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement a...

Zacks Investment Research - 5 months ago

Is (TTOO) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 5 months ago

LEXINGTON, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that on June 16, 2020 it r...

GlobeNewsWire - 5 months ago

Three new appointments add significant clinical and commercialization experience and expand board diversity Three new appointments add significant clinical and commercialization experience and...

Zacks Investment Research - 5 months ago

Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.

Zacks Investment Research - 6 months ago

Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.

GlobeNewsWire - 6 months ago

Achievement Underscores the Clinical Value of Company’s Rapid Diagnostic Test for Sepsis-causing Bacterial Pathogens in Bloodstream Achievement Underscores the Clinical Value of Company’s Rapi...

Seeking Alpha - 6 months ago

T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

T2 Biosystems' (TTOO) first-quarter performance is likely to reflect growth in product revenues.

GlobeNewsWire - 7 months ago

LEXINGTON, Mass., April 15, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement ...

GlobeNewsWire - 8 months ago

New COVID-19 assay will be adapted to run on T2 Biosystems’ FDA-cleared T2Dx® Instrument New COVID-19 assay will be adapted to run on T2 Biosystems’ FDA-cleared T2Dx® Instrument

GlobeNewsWire - 8 months ago

Suspends 2020 Financial Guidance Suspends 2020 Financial Guidance

GlobeNewsWire - 8 months ago

Contract recognizes products that bring improvements to the health care industry Contract recognizes products that bring improvements to the health care industry

Seeking Alpha - 9 months ago

T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 10 months ago

LEXINGTON, Mass., Jan. 17, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products f...

GlobeNewsWire - 10 months ago

LEXINGTON, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, t...

GlobeNewsWire - 10 months ago

Enters Exclusive Distribution Agreement to Expand Sales in Israel Enters Exclusive Distribution Agreement to Expand Sales in Israel

About TTOO

T2 Biosystems, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as we... [Read more...]

Industry
Diagnostics & Research
IPO Date
Aug 7, 2014
CEO
John McDonough
Employees
118
Stock Exchange
NASDAQ
Ticker Symbol
TTOO
Full Company Profile

Financial Performance

In 2019, T2 Biosystems's revenue was $8.34 million, a decrease of -20.62% compared to the previous year's $10.50 million. Losses were -$59.01 million, 15.4% more than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for T2 Biosystems is 3.22, which is an increase of 170.59% from the latest price.

Price Target
$3.22
(170.59% upside)